Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Acquired by Point72 Europe London LLP

Key Points

• Point72 Europe London LLP increased its stake in Structure Therapeutics Inc. by 188.7% to 90,697 shares, valued at approximately $1.57 million.
• The company reported a loss of ($0.36) earnings per share, missing analysts' estimates, while analysts predict an average of ($0.82) EPS for the current fiscal year.
• Structure Therapeutics has a market cap of $1.11 billion and its shares have seen a price range between $13.22 and $45.37 over the past year.

Point72 Europe London LLP increased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 188.7% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 90,697 shares of the company's stock after purchasing an additional 59,277 shares during the quarter. Point72 Europe London LLP owned 0.16% of Structure Therapeutics worth $1,570,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in GPCR. DAFNA Capital Management LLC boosted its stake in Structure Therapeutics by 66.2% in the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock valued at $1,021,000 after purchasing an additional 23,500 shares during the period. Trexquant Investment LP lifted its stake in Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after buying an additional 67,464 shares during the period. Jump Financial LLC acquired a new position in Structure Therapeutics during the first quarter worth $532,000. Monashee Investment Management LLC lifted its position in shares of Structure Therapeutics by 121.9% during the first quarter. Monashee Investment Management LLC now owns 292,862 shares of the company's stock valued at $5,069,000 after purchasing an additional 160,862 shares in the last quarter. Finally, Capital Fund Management S.A. raised its position in Structure Therapeutics by 18.7% in the first quarter. Capital Fund Management S.A. now owns 79,656 shares of the company's stock worth $1,379,000 after acquiring an additional 12,521 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Guggenheim decreased their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a report on Thursday, August 7th. JMP Securities cut their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Finally, HC Wainwright reduced their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Trading Down 1.8%

GPCR stock traded down $0.37 during midday trading on Wednesday, hitting $19.71. 6,056,650 shares of the company's stock were exchanged, compared to its average volume of 831,856. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $45.37. The business has a 50-day simple moving average of $18.87 and a two-hundred day simple moving average of $20.77. The stock has a market capitalization of $1.14 billion, a PE ratio of -18.77 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.